Jump to content

Talk:Covaxin

Page contents not supported in other languages.
From Wikipedia, the free encyclopedia
(Redirected from Talk:BBV152)


Requested move 9 May 2021

[edit]
The following is a closed discussion of a requested move. Please do not modify it. Subsequent comments should be made in a new section on the talk page. Editors desiring to contest the closing decision should consider a move review after discussing it on the closer's talk page. No further edits should be made to this discussion.

The result of the move request was: page moved. Murtaza.aliakbar (talk) 09:23, 16 May 2021 (UTC)[reply]



BBV152Covaxin – As per WP:COMMONNAME. Bharat Biotech, the developing company markets it as COVAXIN. They are developing another vaccine, but that's not named commercially, so it's BBV154 only. Whereas, COVAXIN case is the opposite, bharatbiotech.com  Saha ❯❯❯ Stay safe  18:08, 9 May 2021 (UTC)[reply]

Edit to the move request, BBV152Covaxin.  Saha ❯❯❯ Stay safe  05:30, 10 May 2021 (UTC)[reply]
information Note: I have modified the request per above. Run n Fly (talk) 17:10, 10 May 2021 (UTC)[reply]
The discussion above is closed. Please do not modify it. Subsequent comments should be made on the appropriate discussion page. No further edits should be made to this discussion.

A Commons file used on this page or its Wikidata item has been nominated for deletion

[edit]

The following Wikimedia Commons file used on this page or its Wikidata item has been nominated for deletion:

Participate in the deletion discussion at the nomination page. —Community Tech bot (talk) 07:02, 30 June 2021 (UTC)[reply]

Semi-protected edit request on 16 July 2021

[edit]

The efficacy section is unclear, as it does not clearly specify the overall efficacy of the vaccine.

Please add to the section:

The overall efficacy of Covaxin in 77.8%.

Sources: https://timesofindia.indiatimes.com/india/covaxins-overall-efficacy-77-8-65-2-effective-against-delta-variant-bharat-biotech/articleshow/84087789.cms https://www.gavi.org/vaccineswork/indias-covaxin-vaccine-shows-high-efficacy-against-covid-19-infections-phase-3 Dhruv Malik (talk) 08:07, 16 July 2021 (UTC)[reply]

 Comment: User:Dhruv Malik, We need to present all the cases. See for example (https://en.wikipedia.org/wiki/Oxford–AstraZeneca_COVID-19_vaccine#Effectiveness). Thus, its correctly represented and requires no change. 2402:3A80:6E3:2F77:7193:D3BB:C7EC:25DE (talk) 18:33, 21 July 2021 (UTC)[reply]

This is a 2-dose vaccine. Dosing interval is... how many weeks?

[edit]

It should be mentioned in quite beginning of this article that this is a 2-dose vaccine.

--ee1518 (talk) 16:38, 4 September 2021 (UTC)[reply]

Semi-protected edit request on 12 November 2021

[edit]

Please replace the phase-III preprint reference with this peer reviewed article[1] at the Covaxin#Efficacy and Covaxin#Phase_III_trials sections.

References

  1. ^ Ella, Raches; Reddy, Siddarth; Blackwelder, William; Potdar, Varsha; Yadav, Pragya; Sarangi, Vamshi; Aileni, Vinay K; Kanungo, Suman; Rai, Sanjay; Reddy, Prabhakar; Verma, Savita; Singh, Chandramani; Redkar, Sagar; Mohapatra, Satyajit; Pandey, Anil; Ranganadin, Pajanivel; Gumashta, Raghavendra; Multani, Manish; Mohammad, Shameem; Bhatt, Parul; Kumari, Laxmi; Sapkal, Gajanan; Gupta, Nivedita; Abraham, Priya; Panda, Samiran; Prasad, Sai; Bhargava, Balram; Ella, Krishna; Vadrevu, Krishna Mohan (November 2021). "Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial". The Lancet: S0140673621020006. doi:10.1016/S0140-6736(21)02000-6.

2402:3A80:6CF:BBB9:CD3F:2714:94D5:8EC5 (talk) 10:36, 12 November 2021 (UTC)[reply]

 Done Abrilando232 (talk) 04:54, 13 November 2021 (UTC)[reply]

9165090187

[edit]

9165090187 — Preceding unsigned comment added by 2409:4043:4C81:3D22:7021:FEB3:28BD:F663 (talk) 13:35, 22 February 2022 (UTC)[reply]